Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer

Imagem de Miniatura
Arquivos
art_SZOR_Neutrophillymphocyte_ratio_is_associated_with_prognosis_in_patients_2018.PDF (685.25 KB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
JOURNAL OF SURGICAL ONCOLOGY, v.117, n.5, Special Issue, p.851-857, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and ObjectivesThe role of inflammation in cancer development is a well-known phenomenon that may be represented by the neutrophil-lymphocyte ratio (NLR). The present research intends to determine the impact of NLR on the survival outcome of patients with gastric cancer (GC), and to evaluate its use as a stratification factor for the staging groups. MethodsData regarding clinical characteristics, surgery, pathology, and follow-up were retrospectively collected from our single-center prospective database. Blood samples were obtained before surgery. ResultsA total of 383 patients (231 males) who underwent gastrectomy with lymphadenectomy were evaluated between 2009 and 2016. NLR established cutoff was 2.44, and patients were divided in NLR 2.44 (hNLR) and <2.44 (lNLR). hNLR patients (38.4% of the cases) had lower disease-free survival and overall survival (OS) compared to lNLR patients (P=0.047 and P=0.045, respectively). Risk stratification according to NLR value was done in same tumor depth (T4 and <T4), stage (III and <III) and lymph node status (N+ and N-) group of patients. The OS was significantly lower when NLR was high in same tumor depth (P=0.032) and stage (P=0.020), but not in same lymph node status patients (P=0.184). In a multivariate analysis, NLR was an independent factor of worse OS (HR 1.50 95%CI 1.27-4.21, P=0.048). ConclusionA high NLR was an independent risk factor for reduced survival in GC patients submitted to potentially curative resection. Calculating NLR is easily reproducible and may be incorporated in pre-operative evaluation.
Palavras-chave
gastrectomy, gastric cancer, neutrophil-lymphocyte ratio
URI
https://observatorio.fm.usp.br/handle/OPI/28117
Referências
  1. Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
  2. Azab B, 2012, ANN SURG ONCOL, V19, P217, DOI 10.1245/s10434-011-1814-0
  3. Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
  4. BOBB GA, 1967, TOXICOL APPL PHARM, V11, P558, DOI 10.1016/0041-008X(67)90056-7
  5. Chasseuil E, 2017, ACTA DERM VENEREOL, DOI 10. 2340/00015555-2872
  6. Clarke SJ, 2011, CLIN PHARMACOL THER, V90, P475, DOI 10.1038/clpt.2011.122
  7. Gondo T, 2012, UROLOGY, V79, P1085, DOI 10.1016/j.urology.2011.11.070
  8. Graziosi L, 2015, AM J SURG, V209, P333, DOI 10.1016/j.amjsurg.2014.06.014
  9. Hirashima M, 1998, J CANCER RES CLIN, V124, P329, DOI 10.1007/s004320050178
  10. Huang Y, 2017, ONCOTARGETS THER, V10, P1165, DOI 10.2147/OTT.S126637
  11. Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI 10.1007/S101209800016]
  12. Jiang N, 2014, BIOMARKERS, V19, P444, DOI 10.3109/1354750X.2014.926567
  13. Jung MR, 2011, J SURG ONCOL, V104, P504, DOI 10.1002/jso.21986
  14. Khoja L, 2016, CANCER MED-US, V5, P2792, DOI 10.1002/cam4.878
  15. Liang W, 2016, CANCER IMMUNOL RES, V4, P83, DOI 10.1158/2326-6066.CIR-15-0313
  16. Liu CL, 2013, J SURG ONCOL, V107, P493, DOI 10.1002/jso.23270
  17. LIU YK, 1978, CANCER, V41, P1193, DOI 10.1002/1097-0142(197803)41:3<1193::AID-CNCR2820410358>3.0.CO;2-Z
  18. Motomura T, 2013, J HEPATOL, V58, P58, DOI 10.1016/j.jhep.2012.08.017
  19. NAKAHARA K, 1987, J SURG ONCOL, V36, P155, DOI 10.1002/jso.2930360302
  20. Nakajima K, 1998, TUMOR BIOL, V19, P464, DOI 10.1159/000030038
  21. Opdenakker G, 2004, INT J DEV BIOL, V48, P519, DOI 10.1387/ijdb.041796go
  22. Paramanathan A, 2014, SURG ONCOL, V23, P31, DOI 10.1016/j.suronc.2013.12.001
  23. Pasini FS, 2014, J GASTROENTEROL, V49, P1453, DOI 10.1007/s00535-013-0904-0
  24. Peinado H, 2008, CANCER CELL, V14, P347, DOI 10.1016/j.ccr.2008.10.012
  25. Rashid F, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-1
  26. Robert ME, 2008, HUM PATHOL, V39, P9, DOI 10.1016/j.humpath.2007.05.024
  27. RUSSELL SW, 1976, INT J CANCER, V18, P322, DOI 10.1002/ijc.2910180309
  28. Sarraf KM, 2009, J THORAC CARDIOV SUR, V137, P425, DOI 10.1016/j.jtcvs.2008.05.046
  29. Shimada H, 2010, GASTRIC CANCER, V13, P170, DOI 10.1007/s10120-010-0554-3
  30. Speiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80
  31. Stotz M, 2013, BRIT J CANCER, V109, P416, DOI 10.1038/bjc.2013.332
  32. Sun JX, 2016, DIS MARKERS, P1, DOI 10.1155/2016/7862469
  33. TABUCHI T, 1992, ANTICANCER RES, V12, P795
  34. Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
  35. Tunes-da-Silva G, 2011, COMPUT STAT DATA AN, V55, P226, DOI 10.1016/j.csda.2010.02.016
  36. Walczak H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008698
  37. Walsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329
  38. Wang SC, 2016, ANN SURG, V263, P292, DOI 10.1097/SLA.0000000000001189
  39. Xue TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096072
  40. Yamanaka T, 2007, ONCOLOGY-BASEL, V73, P215, DOI 10.1159/000127412
  41. Zhang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111906
  42. Zhang XJ, 2015, INT J SURG, V21, P84, DOI 10.1016/j.ijsu.2015.07.681

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/35
Artigos e Materiais de Revistas Científicas - LIM/37
Artigos e Materiais de Revistas Científicas - LIM/38
Carregar mais